We recently compiled a list of the Billionaire Larry Robbins’ Long-Term Stock Picks. In this article, we are going to take a ...
Humana (HUM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
Growing up with an OB-GYN father, Rachel Blank assumed that most women received excellent gynecological care. In 2024, Allara ...
An arbitrator has determined Prime Therapeutics violated federal and state antitrust laws against the AIDS Healthcare ...
Elevance Health's financial outlook for FY 2025 anticipates GAAP diluted earnings per share (EPS) to be in the range of $30.40 to $31.10 and adjusted diluted EPS to be in the range of $34.15 to $34.85 ...
To create a healthcare strategy that evolves alongside employee needs, employers must build a system that responds to these, ...
Merit Financial Group LLC increased its stake in shares of The Cigna Group (NYSE:CI – Free Report) by 15.7% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned ...
Buying $1000 In CI: If an investor had bought $1000 of CI stock 20 years ago, it would be worth $11,032.06 today based on a ...
We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a ...
Discover how the three largest pharmacy benefit managers are rejecting biosimilars from their formularies, except for their own private-label drugs.
Christopher Sayed, MD, discusses how hidradenitis suppurativa typically presents and looks forward, following the November approval of bimekizumab.